Of patients with brain metastases from melanoma, 40–50% harbor BRAF mutations, and the use of the BRAF inhibitor vemurafenib is associated with 18–20% response rates and dabrafenib yields 30–40% response rates48,49. Here, BRAF is linked to melanoma.